Advertisement

Prognosis of Neuropsychiatric Systemic Lupus Erythematosus

  • Shinsuke Yasuda
Chapter

Abstract

It is still a matter of debate whether mortality rate is higher in SLE patients with neuropsychiatric (NP) symptoms compared to those without them. Probably this situation is based on the difference in the character of each cohort and also on the vagueness of the definition/diagnosis of NPSLE, even after 1999. Although NPSLE has been repeatedly detected as one of the predictive factors for poor prognosis, NPSLE itself is not a common direct cause of death. It is more likely that patients with NPSLE tend to suffer from more recalcitrant lupus disease activities requiring intense immunosuppressive treatment or sometimes too severe to control. However, more and more advanced brain imaging, understanding on neuroscience and pathophysiology of NPSLE, and novel targeted-therapies are emerging. Thus we would expect better prognosis, cognitive/psychological functions and qualities of life for patients with NPSLE in near future.

Keywords

Prognosis Mortality Irreversible damage Cerebrovascular disease Cognitive dysfunction 

Notes

Acknowledgements

I appreciate supports and advice from Drs. Yuichiro Fujieda, Kenji Oku, Yuka Shimizu, Naoki Ohnishi, and Tatsuya Atsumi.

References

  1. 1.
    ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599–608.CrossRefGoogle Scholar
  2. 2.
    Unterman A, et al. Neuropsychiatric syndromes in systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum. 2011;41:1–11.CrossRefPubMedGoogle Scholar
  3. 3.
    Sibley JT, et al. The incidence and prognosis of central nervous system disease in systemic lupus erythematosus. J Rheumatol. 1992;19:47–52.PubMedGoogle Scholar
  4. 4.
    Karassa FB, et al. Predictors of clinical outcome and radiologic progression in patients with neuropsychiatric manifestations of systemic lupus erythematosus. Am J Med. 2000;109:628–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Ginzler EM, et al. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982;25:601–11.CrossRefPubMedGoogle Scholar
  6. 6.
    Jonsen A, et al. Outcome of neuropsychiatric systemic lupus erythematosus within a defined Swedish population: increased morbidity but low mortality. Rheumatology. 2002;41:1308–12.CrossRefPubMedGoogle Scholar
  7. 7.
    Hanly JG, et al. Prospective analysis of neuropsychiatric events in an international disease inception cohort of patients with systemic lupus erythematosus. Ann Rheum Dis. 2010;69:529–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Zirkzee EJ, et al. Mortality in neuropsychiatric systemic lupus erythematosus (NPSLE). Lupus. 2014;23:31–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Arinuma Y, et al. Brain MRI in patients with diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Lupus Sci Med. 2014;1:e000050.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Shimizu Y, et al. Post-steroid neuropsychiatric manifestations are significantly more frequent in SLE compared with other systemic autoimmune diseases and predict better prognosis compared with de novo neuropsychiatric SLE. Autoimmun Rev. 2016;15:786–94.CrossRefPubMedGoogle Scholar
  11. 11.
    Kono M, et al. Long-term outcome in Japanese patients with lupus nephritis. Lupus. 2014;23:1124–32.CrossRefPubMedGoogle Scholar
  12. 12.
    Mok CC, et al. Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum. 2013;65:2154–60.CrossRefPubMedGoogle Scholar
  13. 13.
    Yap DY, Tang CS, Ma MK, Lam MF, Chan TM. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant. 2012;27:3248–54.CrossRefPubMedGoogle Scholar
  14. 14.
    Shinjo SK, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum. 2010;62:855–62.CrossRefPubMedGoogle Scholar
  15. 15.
    Monahan RC, et al. Neuropsychiatric symptoms in systemic lupus erythematosus: impact on quality of life. Lupus. 2017;26:1252–9.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Magro-Checa C, et al. Outcomes of neuropsychiatric events in systemic lupus erythematosus based on clinical phenotypes; prospective data from the Leiden NP SLE cohort. Lupus. 2017;26:543–51.CrossRefPubMedGoogle Scholar
  17. 17.
    Gladman D, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996;39:363–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Magro-Checa C, et al. Changes in white matter microstructure suggest an inflammatory origin of neuropsychiatric systemic lupus erythematosus. Arthritis Rheum. 2016;68:1945–54.CrossRefGoogle Scholar
  19. 19.
    Zirkzee EJ, et al. Prospective study of clinical phenotypes in neuropsychiatric systemic lupus erythematosus; multidisciplinary approach to diagnosis and therapy. J Rheumatol. 2012;39:2118–26.CrossRefPubMedGoogle Scholar
  20. 20.
    Fujieda Y, et al. Predominant prevalence of arterial thrombosis in Japanese patients with antiphospholipid syndrome. Lupus. 2012;21(14):1506.CrossRefPubMedGoogle Scholar
  21. 21.
    Cervera R, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–27.CrossRefPubMedGoogle Scholar
  22. 22.
    Bernatsky S, et al. Mortality related to cerebrovascular disease in systemic lupus erythematosus. Lupus. 2006;15:835–9.CrossRefPubMedGoogle Scholar
  23. 23.
    Otomo K, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012;64:504–12.CrossRefPubMedGoogle Scholar
  24. 24.
    Sciascia S, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology. 2013;52:1397–403.CrossRefPubMedGoogle Scholar
  25. 25.
    Oku K, et al. How to identify high-risk APS patients: clinical utility and predictive values of validated scores. Curr Rheumatol Rep. 2017;19:51.CrossRefPubMedGoogle Scholar
  26. 26.
    Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol. 2014;10:338–47.CrossRefPubMedGoogle Scholar
  27. 27.
    Hanly JG, et al. Screening for cognitive impairment in systemic lupus erythematosus. J Rheumatol. 2012;39(7):1371.CrossRefPubMedGoogle Scholar
  28. 28.
    Denburg SD, Denburg JA. Cognitive dysfunction and antiphospholipid antibodies in systemic lupus erythematosus. Lupus. 2003;12:883–90.CrossRefPubMedGoogle Scholar
  29. 29.
    Hanly JG, et al. Cognitive function in systemic lupus erythematosus: results of a 5-year prospective study. Arthritis Rheum. 1997;40:1542–3.CrossRefPubMedGoogle Scholar
  30. 30.
    Waterloo K, et al. Neuropsychological function in systemic lupus erythematosus: a five-year longitudinal study. Rheumatology. 2002;41:411–5.CrossRefPubMedGoogle Scholar
  31. 31.
    Ainiala H, et al. Validity of the new American College of Rheumatology criteria for neuropsychiatric lupus syndromes: a population-based evaluation. Arthritis Rheum. 2001;45:419–23.CrossRefPubMedGoogle Scholar
  32. 32.
    Hanly JG, et al. Neuropsychiatric events in systemic lupus erythematosus: attribution and clinical significance. J Rheumatol. 2004;31:2156–62.PubMedGoogle Scholar
  33. 33.
    Sanna G, et al. Neuropsychiatric manifestations in systemic lupus erythematosus: prevalence and association with antiphospholipid antibodies. J Rheumatol. 2003;30:985–92.PubMedGoogle Scholar
  34. 34.
    Hirohata S, et al. Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol. 2009;28:1319–23.CrossRefPubMedGoogle Scholar
  35. 35.
    Abe G, et al. Brain MRI in patients with acute confusional state of diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. Mod Rheumatol. 2017;27:278–83.CrossRefPubMedGoogle Scholar
  36. 36.
    Barile-Fabris L, et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis. 2005;64:620–5.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Neuwelt CM, et al. Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med. 1995;98:32–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Stojanovich L, et al. Neuropsychiatric lupus favourable response to low dose i.v. cyclophosphamide and prednisolone (pilot study). Lupus. 2003;12:3–7.CrossRefPubMedGoogle Scholar
  39. 39.
    Neuwelt CM. The role of plasmapheresis in the treatment of severe central nervous system neuropsychiatric systemic lupus erythematosus. Ther Apher Dial. 2003;7:173–82.CrossRefPubMedGoogle Scholar
  40. 40.
    Camara I, et al. Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre. Clin Exp Rheumatol. 2014;32:41–7.PubMedGoogle Scholar
  41. 41.
    Cobo-Ibanez T, et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematosus: a systematic review. Semin Arthritis Rheum. 2014;44:175–85.CrossRefPubMedGoogle Scholar
  42. 42.
    Tokunaga M, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470–5.CrossRefPubMedGoogle Scholar
  43. 43.
    Ginzler E, et al. Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. Arthritis Rheum. 1975;18:27–34.CrossRefPubMedGoogle Scholar
  44. 44.
    Bertsias GK, et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. Ann Rheum Dis. 2010;69:2074–82.CrossRefPubMedGoogle Scholar
  45. 45.
    Khamashta MA, et al. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995;332:993–7.CrossRefPubMedGoogle Scholar
  46. 46.
    Crowther MA, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med. 2003;349:1133–8.CrossRefPubMedGoogle Scholar
  47. 47.
    Finazzi G, et al. A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost. 2005;3:848–53.CrossRefPubMedGoogle Scholar
  48. 48.
    Cohen H, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016;3:e426–36.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Chau SY, Mok CC. Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology. 2003;61:104–7.CrossRefPubMedGoogle Scholar
  50. 50.
    Bethea HN, et al. Redirecting the substrate specificity of heparan sulfate 2-O-sulfotransferase by structurally guided mutagenesis. Proc Natl Acad Sci U S A. 2008;105:18724–9.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of MedicineHokkaido UniversitySapporoJapan

Personalised recommendations